BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

882 related articles for article (PubMed ID: 17403477)

  • 1. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
    Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension.
    Skoro-Sajer N; Bonderman D; Wiesbauer F; Harja E; Jakowitsch J; Klepetko W; Kneussl MP; Lang IM
    J Thromb Haemost; 2007 Mar; 5(3):483-9. PubMed ID: 17319903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions.
    Scelsi L; Ghio S; Campana C; D'Armini AM; Serio A; Klersy C; Piovella F; Viganò M; Tavazzi L
    Ital Heart J; 2004 Aug; 5(8):618-23. PubMed ID: 15554033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
    Jaïs X; D'Armini AM; Jansa P; Torbicki A; Delcroix M; Ghofrani HA; Hoeper MM; Lang IM; Mayer E; Pepke-Zaba J; Perchenet L; Morganti A; Simonneau G; Rubin LJ;
    J Am Coll Cardiol; 2008 Dec; 52(25):2127-34. PubMed ID: 19095129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension.
    Saouti N; de Man F; Westerhof N; Boonstra A; Twisk J; Postmus PE; Vonk Noordegraaf A
    Respir Med; 2009 Jul; 103(7):1013-9. PubMed ID: 19230641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mid-term efficacy of beraprost, an oral prostacyclin analog, in the treatment of distal CTEPH: a case control study.
    Vizza CD; Badagliacca R; Sciomer S; Poscia R; Battagliese A; Schina M; Agati L; Fedele F
    Cardiology; 2006; 106(3):168-73. PubMed ID: 16645271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a single institution experience.
    Saouti N; Morshuis WJ; Heijmen RH; Snijder RJ
    Eur J Cardiothorac Surg; 2009 Jun; 35(6):947-52; discussion 952. PubMed ID: 19272789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension.
    Krug S; Hammerschmidt S; Pankau H; Wirtz H; Seyfarth HJ
    Respiration; 2008; 76(2):154-9. PubMed ID: 17804899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
    Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
    N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
    McLaughlin VV; Genthner DE; Panella MM; Rich S
    N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of long-term treatment with prostacyclin on plasma adrenomedullin in patients with primary pulmonary hypertension].
    Nakayama T; Ishikita T; Matsuura H; Saji T
    J Cardiol; 2001 Nov; 38(5):263-71. PubMed ID: 11729726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Six-minute walk distance as parameter of functional outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension.
    Reesink HJ; van der Plas MN; Verhey NE; van Steenwijk RP; Kloek JJ; Bresser P
    J Thorac Cardiovasc Surg; 2007 Feb; 133(2):510-6. PubMed ID: 17258590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension.
    Kähler CM; Graziadei I; Wiedermann CJ; Kneussl MP; Vogel W
    Wien Klin Wochenschr; 2000 Jul; 112(14):637-40. PubMed ID: 11008327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).
    Klings ES; Hill NS; Ieong MH; Simms RW; Korn JH; Farber HW
    Arthritis Rheum; 1999 Dec; 42(12):2638-45. PubMed ID: 10616012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chronic thromboembolic pulmonary hypertension: surgical treatment with thromboendarterectomy].
    Blázquez JA; Escribano P; Pérez E; López MJ; Gómez MA; Cortina JM
    Arch Bronconeumol; 2009 Oct; 45(10):496-501. PubMed ID: 19656605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation.
    Conte JV; Gaine SP; Orens JB; Harris T; Rubin LJ
    J Heart Lung Transplant; 1998 Jul; 17(7):679-85. PubMed ID: 9703232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.